Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study

Clinical benefit of immune checkpoint blockade in glioblastoma (GBM) is rare, and we hypothesize that tumor clonal evolution and the immune microenvironment are key determinants of response. Here, we present a detailed molecular characterization of the intratumoral and immune heterogeneity in an IDH...

Descripción completa

Detalles Bibliográficos
Autores principales: Restrepo, Paula, Yong, Raymund, Laface, Ilaria, Tsankova, Nadejda, Nael, Kambiz, Akturk, Guray, Sebra, Robert, Gnjatic, Sacha, Hormigo, Adilia, Losic, Bojan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2020
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133743/
https://www.ncbi.nlm.nih.gov/pubmed/31907277
http://dx.doi.org/10.1101/mcs.a004762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133743/
https://www.ncbi.nlm.nih.gov/pubmed/31907277
http://dx.doi.org/10.1101/mcs.a004762

Ejemplares similares